| Share


Melbourne, Australia, Feb. 26, 2020 - Kesem Health, a digital health company revolutionising the diagnosis and management of urological diseases, announced today it succeeded in securing a competitive Commonwealth government Accelerating Commercialisation

Kesem Health will receive $175,000 to advance its commercialisation in the US,  enhance its ability to penetrate global markets, and raise significant growth capital. This is the third AC grant that Kesem has received, taking its funding through the AC program to a total of $1,000,000.

Kesem is proud to have been selected by the office of Minister Karen Andrews, the AC committee, and the Australian Government Department of Industry, Innovation and Science through the competitive Accelerating Commercialisation grant process as part of the Entrepreneurs’ Programme.

Gil Hidas, Kesem Health’s CEO, said: “The Accelerating Commercialisation program is critical to the success of Australia’s well-respected innovative eco-system. Companies like Kesem, undertaking early commercialisation, urge all levels of government to continue to advance research and development incentives of this kind”.

It is important to note that Accelerating Commercialisation, coupled with the R&D Tax Incentive, are vital for Australia to build companies that will create a sustainable industry and jobs-based innovation in healthcare.

Kesem Health is proud to be supported by the Australian Government through Accelerating Commercialisation, an element of the of the Entrepreneurs' Programme.

 About Kesem Health and the iUFlow™ solution.
Kesem Health focuses on using the iUFlow™ solution to improve, simplify, and reduce the cost of the diagnosis and management of Lower Urinary Tract diseases including Benign Prostatic Hyperplasia (BPH), Overactive Bladder (OAB), and Nocturia. Kesem is developing the world’s largest set of urinary flow data, utilising the iUFlow - a low-cost, quick, and accurate method of measuring urinary output – information that is critical for the diagnosis and management of urological conditions that affect more than 16% of the adult and juvenile population worldwide.


For more information, 

visit: www.KesemHealth.com
SOURCE Kesem Health

Media Contact: assist@kesemHealth.com